mRNA: Fulfilling the Promise of Gene Therapy

Molecular Therapy

Volumn 23, Issue 9, 2015, Pages 1416-1417

  Weissman, Drew ^a   Karikó, Katalin ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BIONTECH AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IN VITRO TRANSCRIBED MRNA; LIPID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; NUCLEOSIDE; POLYADENYLIC ACID; PSEUDOURIDINE; RNA; UNCLASSIFIED DRUG; URIDINE;

CYTOKINE PRODUCTION; DRUG FORMULATION; GC RICH SEQUENCE; GENE THERAPY; GENETIC ENGINEERING; HEMATOPOIESIS; IMMUNOGENICITY; MOLECULAR THERAPY; NONHUMAN; NOTE; NUCLEIC ACID BASE SUBSTITUTION; RNA SEQUENCE; RNA TRANSCRIPTION; ANIMAL; GENE EXPRESSION; GENETICS; HUMAN;

ANIMALS; GENE EXPRESSION; GENETIC THERAPY; HUMANS; RNA, MESSENGER;

EID: 84940653144     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.138     Document Type: Note

References (12)

1. Sahin, U, Kariko, K and Tureci, O (2014). mRNAbased therapeutics-developing a new class of drugs. Nat Rev Drug Discov 13: 759-780.
2. Jirikowski, GF, Sanna, PP, Maciejewski-Lenoir, D and Bloom, FE (1992). Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255: 996-998.
3. Kariko, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175.
4. Thess, A, Grund, S, Mui, BL, Hope, MJ, Baumhof, P, Fotin-Mleczek, M et al. (2015). Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23: 1456-1464
5. Kariko, K, Muramatsu, H, Welsh, FA, Ludwig, J, Kato, H, Akira, S et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16: 1833-1840.
6. Kariko, K, Muramatsu, H, Keller, JM and Weissman, D (2012). Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridinecontaining mRNA encoding erythropoietin. Mol Ther 20: 948-953.
7. Kariko, K, Muramatsu, H, Ludwig, J and Weissman, D (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, proteinencoding mRNA. Nucleic Acids Res 39: e142.
8. Diebold, SS, Massacrier, C, Akira, S, Paturel, C, Morel, Y and Reis e Sousa, C (2006). Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 36: 3256-3267.
9. Heil, F, Hemmi, H, Hochrein, H, Ampenberger, F, Kirschning, C, Akira, S et al. (2004). Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303: 1526-1529.
10. Saito, T, Owen, DM, Jiang, F, Marcotrigiano, J and Gale, M Jr (2008). Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454: 523-527.
11. Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154-157.
12. Koski, GK, Kariko, K, Xu, S, Weissman, D, Cohen, PA and Czerniecki, BJ (2004). Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 172: 3989-3993.